| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/21/2004 | EP1411124A2 Human cancer antigen of tyrosinase-related protein 1 and 2 and genes encoding same |
| 04/21/2004 | EP1411064A2 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours |
| 04/21/2004 | EP1411063A1 Peptide nucleic acids |
| 04/21/2004 | EP1411057A1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them |
| 04/21/2004 | EP1411056A2 Imidazo[1,2-a]pyridine compounds that inhibit gastric acid secretion, pharmaceutical compositions thereof, and processes for their preparation |
| 04/21/2004 | EP1411055A1 Thiazolidinedione derivative and its use as antidiabetic |
| 04/21/2004 | EP1411054A1 Thiazolidinedione derivative and its use as antidiabetic |
| 04/21/2004 | EP1411052A1 Benzo-fused 5-membered hetrocycle compounds,process for preparation of the same, and use thereof |
| 04/21/2004 | EP1411049A1 Estrogen Agonists/Antagonists |
| 04/21/2004 | EP1411046A1 QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF−PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME |
| 04/21/2004 | EP1410822A1 Oxa(thia)zolidine compounds, process for preparation thereof and anti-inflammatory agents |
| 04/21/2004 | EP1410808A1 Optic nerve protecting agents containing alpha 1 receptor blocker as the active ingredient |
| 04/21/2004 | EP1410800A1 Use of 1- 4-(5-cyanoindol-3-yl)butyl -4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiologically acceptable salts |
| 04/21/2004 | EP1410799A1 Methods and pharmaceutical compositions for inhibiting tumour cell growth |
| 04/21/2004 | EP1410798A2 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| 04/21/2004 | EP1410797A1 Solid oral dosage forms comprising valsartan |
| 04/21/2004 | EP1410796A2 New therapeutic uses for potassium channel openers |
| 04/21/2004 | EP1410795A1 Remedies for allergic eye diseases |
| 04/21/2004 | EP1410794A1 Soft capsules |
| 04/21/2004 | EP1410792A1 Microparticles |
| 04/21/2004 | EP1410791A1 Orally administrable galenic form comprising metformine and an absorption-promoting agent |
| 04/21/2004 | EP1410790A1 Submicron-liposome containing triterpenoid and a method for preparing the same |
| 04/21/2004 | EP1410722A1 Weight loss kit and method for losing weight |
| 04/21/2004 | EP1410721A1 Process for manufacturing a palatinose-containing enteral food |
| 04/21/2004 | EP1410036A2 Methods and compositions for diagnosing and treating a subject having depression |
| 04/21/2004 | EP1410035A2 Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators |
| 04/21/2004 | EP1410018A1 Method for detecting modultators of notch signalling |
| 04/21/2004 | EP1409740A2 Asthma-associated gene |
| 04/21/2004 | EP1409736A2 Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
| 04/21/2004 | EP1409710A1 Nucleic acid and corresponding protein entitled 161p5c5 useful in treatment and detection of cancer |
| 04/21/2004 | EP1409705A1 A process for the production of an inhibitor of human platelet aggregation and soybean lipoxygenase |
| 04/21/2004 | EP1409683A2 i HELICOBACTER /i PROTEINS, NUCLEIC ACIDS AND USES THEREOF |
| 04/21/2004 | EP1409680A2 Novel human proton-gated channels |
| 04/21/2004 | EP1409672A2 Antisense oligonucleotides which can inhibit the formation of capillary tubes by endothelial cells |
| 04/21/2004 | EP1409670A2 Synthetic double stranded oligonucleotides for targeted inhibition of gene expression |
| 04/21/2004 | EP1409656A1 Screening non-peptide, non-steroid invertebrate pheromone compounds for mitogen-activated protein kinase modulating activity |
| 04/21/2004 | EP1409653A1 Viral mutants that selectively replicate in targeted human cancer cells |
| 04/21/2004 | EP1409639A1 Epidermal growth factor receptorantisense oligonucleotides |
| 04/21/2004 | EP1409548A2 Ligands to enhance cellular uptake of biomolecules |
| 04/21/2004 | EP1409526A2 An inducer of apoptosis |
| 04/21/2004 | EP1409523A2 Pancam nucleic acids and polypeptides |
| 04/21/2004 | EP1409513A1 Methylene-4-azasteroids |
| 04/21/2004 | EP1409509A2 Antisense modulation of c-reactive protein expression |
| 04/21/2004 | EP1409506A1 Methods and compositions for rnai mediated inhibition of gene expression in mammals |
| 04/21/2004 | EP1409502A2 Solvent-free anthracycline derivatives |
| 04/21/2004 | EP1409494A1 Stabilized derivatives of ascorbic acid -3- phosphate |
| 04/21/2004 | EP1409492A1 An improved method for preparation of cefuroxime axetil |
| 04/21/2004 | EP1409491A2 Thienopyrimidine-based inhibitors of the src family |
| 04/21/2004 | EP1409490A1 2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza-cyclopenta a]naphthalenyl derivatives with antipsychotic activity |
| 04/21/2004 | EP1409489A1 6-phenyldihydropyrrolopyrimidinedione derivatives |
| 04/21/2004 | EP1409488A1 Imidazo-triazine derivatives as ligands for gaba receptors |
| 04/21/2004 | EP1409487A1 Pteridinones as kinase inhibitors |
| 04/21/2004 | EP1409486A1 Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives |
| 04/21/2004 | EP1409485A1 Novel immunomodulating compounds |
| 04/21/2004 | EP1409483A1 Arylsulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors |
| 04/21/2004 | EP1409481A1 Quinoline derivatives and their use as tyrosine kinase inhibitors |
| 04/21/2004 | EP1409480A1 Pyrrolo-indole and pyrrolo-quinoline derivatives as prodrugs for tumour treatment |
| 04/21/2004 | EP1409477A1 Piperidine derivatives as nmda receptor antagonists |
| 04/21/2004 | EP1409476A1 Pharmaceutical compounds with serotonin receptor activity |
| 04/21/2004 | EP1409472A1 Method for the preparation of escitalopram |
| 04/21/2004 | EP1409468A2 Guanidinobenzamides as mc4-r agonists |
| 04/21/2004 | EP1409467A1 Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors |
| 04/21/2004 | EP1409466A2 Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis |
| 04/21/2004 | EP1409463A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 04/21/2004 | EP1409461A1 Novel azole or triazole derivatives, method for preparing same and use thereof as fungicides |
| 04/21/2004 | EP1409455A1 Prostaglandin analogues-as ep4 receptor agonists |
| 04/21/2004 | EP1409453A1 Novel diamines having a casr modulating activity |
| 04/21/2004 | EP1409452A1 Sulfonamide derivatives |
| 04/21/2004 | EP1409450A1 N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds |
| 04/21/2004 | EP1409448A1 Process for the preparation of (r)- or (s)-aminocarnitine inner salt, the salts and derivatives thereof |
| 04/21/2004 | EP1409446A1 Method for the nitration of phenolic compounds |
| 04/21/2004 | EP1409443A2 Non-halogenated naphthol compounds, antimicrobial compositions containing the same, and methods of using the same |
| 04/21/2004 | EP1409101A1 Formation of small crystals |
| 04/21/2004 | EP1409080A1 Medicament inhibiting sodium/calcium exchange system |
| 04/21/2004 | EP1409076A2 Method and apparatus for treating tumors using low strength electric fields |
| 04/21/2004 | EP1409025A1 Vector encoding human globlin gene and use thereof in treatment of hemoglobinopathies |
| 04/21/2004 | EP1409023A1 Compositions and preparation methods for bioavailable oral aceaceclofenac dosage forms |
| 04/21/2004 | EP1409022A1 Pharmaceutical vehicle |
| 04/21/2004 | EP1409021A2 Formulation comprising fulvestrant |
| 04/21/2004 | EP1409020A1 Antacid chewing gum products coated with high viscosity materials |
| 04/21/2004 | EP1409019A2 Gd3 synthesis inhibitors for treating neuropathological disorders |
| 04/21/2004 | EP1409016A2 Antibodies to opgl |
| 04/21/2004 | EP1409007A2 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof |
| 04/21/2004 | EP1409005A1 Modulators of notch signalling for use in immunotherapy |
| 04/21/2004 | EP1409001A2 Mineral-protein preparations (mpp) and neuropathies in diabetes |
| 04/21/2004 | EP1408999A1 Compositions addressing inflammation and/or degenerative disorders |
| 04/21/2004 | EP1408992A2 Pharmaceutical composition for treating hypercholesterolaemia |
| 04/21/2004 | EP1408990A2 Use of hyaluronic acid uronides for the treatment of inflammatory processes |
| 04/21/2004 | EP1408989A2 Method and material for treating immune diseases |
| 04/21/2004 | EP1408988A1 Compositions of orally administered nutritional supplements to repair articular cartilage |
| 04/21/2004 | EP1408987A2 Tetracycline compounds having target therapeutic activities |
| 04/21/2004 | EP1408984A2 Organo-phosphorous compounds for activating gamma/delta t cells |
| 04/21/2004 | EP1408983A2 Method of treating hyperproliferative diseases using active vitamin d analogues |
| 04/21/2004 | EP1408982A1 Pharmaceutical compositions for treatment of digestive disorders and associated diseases |
| 04/21/2004 | EP1408981A1 Methods for preventing antipsychotic-induced weight gain |
| 04/21/2004 | EP1408977A1 A combination therapy for the treatment of heart failure |
| 04/21/2004 | EP1408976A1 Treatment for attention-deficit hyperactivity disorder |
| 04/21/2004 | EP1408975A2 Methods for the treatment of cancer with irinotecan based on cyp3a5 |
| 04/21/2004 | EP1408974A2 Methods for treatment of cancer using irinotecan based on ugt1a1 |
| 04/21/2004 | EP1408973A2 Means and methods for improved treatment of cancer based on mrp1 |